Cosmos Health Inc. (COSM) · Oct 22, 2026 · Guidance
Guidance reaffirmed — FY26 revenue above $90M; FY29 revenue target $200.6M
Cosmos Health’s guidance update keeps the $90M 2026 target intact, but the real swing factor is whether its high-margin U.S. subscription launch scales.
Cosmos Health is transitioning from a low-margin pharmaceutical distributor into a more integrated healthcare platform built around contract manufacturing, proprietary brands and a new U.S. direct-to-consumer subscription business. The filing adds detail to that strategy, but not a new numerical outlook: the company had already reported preliminary nine-month revenue of about $54.3 million and reaffirmed revenue above $90 million on October 7, while the $15 million fourth-quarter U.S. revenue expectation was disclosed on October 19.
| Metric | Filing figure | Comparison / implication |
|---|---|---|
| Nine-month 2026 revenue | ~$54.3M | +19% year over year (Nine months) |
| Q3 2026 revenue | ~$17.4M | Record third quarter (Nine months) |
| FY2026 revenue outlook | >$90M | +~38% versus FY2025 (Nine months) |
| Implied Q4 2026 revenue | ~$35.7M or more | +~81% versus Q4 2025 (Nine months) |
| Q4 U.S. revenue | ~$15M | ~$10.5M gross profit; ~70% gross margin (U.S. revenue) |
| FY2029 revenue target | $200.6M | +207% versus FY2025 (Revenue of $200.6 million) |
| FY2029 adjusted EBITDA target | $44.2M | Versus negative $3.4M in FY2025 (Revenue of $200.6 million) |
The outlook is confirmed, not upgraded. Management says, “We reaffirm our expectation that full-year 2026 revenue will surpass $90million.” That makes this an in-line guidance event rather than a beat: the filing preserves the existing target and supplies a more aggressive implied fourth quarter, but does not raise the bar or provide audited earnings, cash flow or profitability results.
The U.S. subscription launch is the genuinely new operating detail. Active subscriptions reached 8,940, up 42% in five days, and management expects roughly $15 million of fourth-quarter U.S. revenue at about a 70% gross margin. The filing states, “With an expected gross margin of approximately 70%, compared with a Company-wide gross margin of 12.1% in fiscal 2025, the U.S. business is a significant driver of the margin expansion set out in our strategy.” 〔0〕 Strategically, that matters more than the headline revenue growth because the new channel could change the company’s revenue mix and margin profile.
The risk is execution, not demand framing. More than half of the projected subscription revenue—about $8.2 million of $11.5 million—comes from first orders, while renewals contribute about $3.3 million. That means the filing demonstrates rapid customer acquisition, but only limited evidence yet on retention, repeat purchasing and the cost of acquiring customers. The company itself notes that “the durability of this business will depend on renewals, retention and the efficiency of customer acquisition.” 〔1〕
The established business is improving, but the step-up still depends on a large Q4 ramp. Cana’s pipeline has grown to more than 32.7 million units and CosmoFarm is operating across more than 1,500 pharmacies, supporting the core-segment foundation. However, the implied $35.7 million fourth quarter is nearly double the $17.4 million Q3 run rate, and the established-segment contribution is explicitly an implication of consolidated guidance rather than separate guidance. That leaves the forecast dependent on converting pipeline volumes and a very rapid U.S. launch into recognized revenue on schedule.
Bottom line: This filing strengthens the case that Cosmos Health’s business mix is changing, especially through high-margin U.S. subscriptions, but it does not improve the formal outlook versus what was already public. The next meaningful proof point is audited Q3 financials and evidence that the unusually large Q4 ramp is converting into repeatable revenue and cash generation.
Full Q3 results and audited nine-month financials
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!